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Abstract 
Background and objectives: We investigated the effect of Nitrous Oxide (N2O) on controlled 
hypotension in low-ﬂ ow isoﬂ urane-dexmedetomidine anesthesia in terms of hemodynamics, 
anesthetic consumption, and costs.
Methods: We allocated forty patients randomly into two equal groups. We then maintained 
dexmedetomidine infusion (0.1 μg.kg-1.min-1) for 10 minutes. Next, we continued it until the last 
30 minutes of the operation at a dose of 0.7 μg.kg-1.hour-1. We administered thiopental (4-6 mg.
kg-1) and 0.08-0.12 mg.kg-1 vecuronium bromide at induction for both groups. We used isoﬂ urane 
(2%) for anesthesia maintenance. Group N received a 50% O2-N2O mixture and Group A received 
50% O2-air mixture as carrier gas. We started low-ﬂ ow anesthesia (1 L.min
-1) after a 10-minute 
period of initial high ﬂ ow (4.4 L.min-1). We recorded values for blood pressure, heart rate, 
peripheral O2 saturation, inspiratory isoﬂ urane, expiratory isoﬂ urane, inspiratory O2, expiratory 
O2, inspiratory N2O, expiratory N2O, inspiratory CO2, CO2 concentration after expiration, Minimum 
Alveolar Concentration. In addition, we determined the total consumption rate of fentanyl, 
dexmedetomidine and isoﬂ urane as well as bleeding.
Results: In each group the heart rate decreased after dexmedetomidine loading. After intubation, 
values were higher for Group A at one, three, ﬁ ve, 10, and 15 minutes. After intubation, the 
patients reached desired hypotension values at minute ﬁ ve for Group N and at minute 20 for 
group A. MAC values were higher for Group N at minute one, three, ﬁ ve, 10, and 15 (p < 0.05). 
FiO2 values were high between minute ﬁ ve and 60 for Group A, while at minute 90 Group N values 
were higher (p < 0.05). Fi Iso (inspiratuvar isoﬂ uran) values were lower in Group N at minute 15 
and 30 (p < 0.05). 
Conclusion: By using dexmedetomidine instead of nitrous oxide in low ﬂ ow isoﬂ urane anesthesia, 
we attained desired MAP levels, sufﬁ cient anesthesia depth, hemodynamic stability and safe 
inspiration parameters. Dexmedetomidine infusion with medical air-oxygen as a carrier gas 
represents an alternative anesthetic technique.
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Introduction
Controlled hypotension is a method used to improve the surgical 
environment by providing a dry area in middle ear surgery 1. 
For this purpose, patient position and ventilation control can 
be supplemented with pharmacologic agents like vasodilators, 
beta-blockers, ganglion blockers and high dose potent inhala-
tion anesthetics 1-5.
For controlled hypotension, inhalation agents have poten-
tial beneﬁ ts 5, such as ease of administration and availability, 
hypotensive and anesthetic effects, and rapid clearance. 
Isoﬂ urane decreases systemic vascular resistance and maintains 
cardiac output at normal levels, while reducing mean arterial 
pressure. However, in some patients rebound hypertension is 
observed, which prevents reﬂ ex sympathetic stimulation and 
maintenance of desired hypotension levels 6. For this reason, 
additional medicines are often used to alleviate these adverse 
effects 7-9.
Dexmedetomidine is a α2-adrenoceptor agonist used as a 
sedative, analgesic, and anxiolytic agent that affects heart rate 
and decreases arterial pressure. Dexmedetomidine is beneﬁ cial 
for controlled hypotension 10.
In middle ear surgeries, when the tympanic membrane 
is placed the middle ear becomes a closed space and the 
membrane could detach from its original placement if nitrous 
oxide diffuses into this space. As such, nitrous oxide should 
be avoided during tympanoplasty or when cutting the graft 
before placement 11. To avoid the harmful effects of nitrous 
oxide, inhalation anesthesia using low ﬂ ow techniques and 
other agents can be used 12.
The economic and ecological drawbacks of anesthetic gas 
use can be addressed using low ﬂ ow anesthetic techniques. 
By using re-inspiration techniques at high levels, anesthetic 
gas consumption and pollution decreases to minimal levels, as 
the contamination of the operating room, while any harmful 
effects are not increased. 
We investigated the effects of nitrous oxide in middle 
ear surgery patients using controlled hypotension created by 
dexmedetomidine and isoﬂ urane in low ﬂ ow anesthesia. 
Methods
 The Institution’s ethics committee approved this study and 
informed consent was obtained from all patients. Forty pa-
tients of ages between 18 and 61 years and ASA I or ASA II 
physical status scheduled to undergo middle ear surgery were 
included in this prospective, randomized study. Patients with 
liver failure, diabetes mellitus, cardiovascular system pathol-
ogy, anemia, drug allergies, bleeding disorders, or pregnancy 
were excluded, as were patients using medications affecting 
the coagulation system. All patients were included in the 
statistical evaluations and all completed the study. Leakage 
control of anesthesia circuits and gas monitor calibration was 
carried out before each operation. For each operation single 
use anesthesia circuits and bacteria ﬁ lters were employed. 
The CO2 absorbent was changed daily.
We did not administer any premedication to the patients. 
We monitored electrocardiography (ECG), heart rate (HBR), 
noninvasive arterial blood pressure (NABP) and peripheral 
oxygen saturation (SpO2) in the operating room with an ADU 
S/5 anesthesia device (Datex–Ohmeda, Finland). Intravenous 
vascular access (IV) was established via 18G (gauge) or 20G 
intravenous cannula and Ringer Lactate infusion initiated with 
a 5-10 mL.kg-1. Preoxygenation was provided with 100% O2 via 
face mask for ten minutes.
A 22G catheter was placed in the radial artery of the 
non-dominant hand for invasive blood pressure monitoring. 
After reading basal values, we started dexmedetomidine 
serum infusion (4 μg.mL-1 in a total volume of 50 mL). After 
dexmedetomidine infusion by injector type infusion pump for 
10 minutes at a dose of 0.1 μg.kg-1.min-1, heart rate and blood 
pressure values were recorded. Dexmedetomidine infusion was 
continued until the last 30 minutes of the operation at a dose 
of 0.7 μg.kg-1.hour-1.
For anesthesia induction, we administered 4–6 mg kg-1 
thiopental (Pental Sodyum, İbrahim Ethem Ulagay İlaç Sanayi, 
İstanbul, Turkey) and 0.08-0.12 mg.kg-1 vecuronium bromide 
(Norcuron, Organon, Oss, Holland) until the thiopental wink 
reﬂ ex disappeared, after which we intubated the patient. 
After endotracheal intubation, we connected all patients to 
an ADU S/5 anesthesia device (Datex-Ohmeda, Finland) and 
maintained the tidal volume at 8-10 mL.kg-1 at 12 breaths.min-1. 
A gas analyzer monitor was used for all patients and soda lime 
(Sorbo-Lime®) was used as a CO2 absorbent. 
Patients were randomly assigned to two groups (N and A) 
using sealed envelopes chosen by the patients before the study. 
The fresh gas ﬂ ow was as follows: 4.4 L.min-1 (O2/N2O = 1.4/3) 
containing 1.5% isoﬂ urane after induction for providing deni-
trogenization and improving anesthesia. After 10 minutes, we 
reduced Group N (n = 20) fresh gas ﬂ ow to 1 L.min-1 50% O2 in 
N2O, providing a FiO2 value above 0.30 and 2-2.5% isoﬂ urane 
was administered.  Twenty minutes before tympanic membrane 
placement, we stopped the nitrous oxide ﬂ ow and isoﬂ urane 
administration continued at 50% O2 in air with 2-2.5% isoﬂ u-
rane. For Group A (n = 20), after 10 minutes, fresh gas ﬂ ow 
was reduced to 1 L.min-1 50% O2 in air providing a FiO2 value 
above 0.30 and 2-2.5% isoﬂ urane was administered.
We chose the isoﬂ urane concentration at values where the 
baseline MAP is decreased by 30% and was stopped 10 minutes 
before the end of the operation. Fresh gas ﬂ ow at 6 L.min-1 
100% O2 was administered 5 minutes before the end of the 
operation. After extubation values were recorded, the patients 
were extubated. Heart rate (HR), mean arterial pressure (MAP), 
peripheral O2 saturation (SpO2), inspiratory isoﬂ urane (Fi Iso), 
expiratory isoﬂ urane (ETIso), inspiratory O2 (FiO2), expiratory 
O2 (ETO2), inspiratory N2O (FiN2O), expiratory N2O (ETN2O), 
inspiratory CO2 (FiCO2), CO2 concentration after expiration 
(ETCO2), Minimum Alveolar Concentration (MAC), respiratory 
tract plateau pressure (Pplato) values were recorded before 
and after dexmedetomidine loading, after zero, three, ﬁ ve, 
10, and 15 minutes after intubation at ﬁ ve minutes intervals 
to minute 60 and then at 15 minutes intervals. During surgery, 
monitors were adjusted so that the end tidal carbon dioxide 
(ETCO2) was between 35-40 mm Hg and FiO2 was above 30%. 
When ETCO2 rose above 40 mm Hg, or FiO2 or SpO2 fell below 
30% or 95, respectively, fresh gas ﬂ ow rate was increased to 
4.4 L.min-1 and those patients were then excluded from the 
study.
Alfentanil was administered by IV at 7 μg.kg-1 as an ad-
ditional analgesic when MAP increased by more than 20% of 
control values, and isoﬂ urane concentrations were decreased 
when MAP fell by more than 20%, whereupon 10 mg ephedrine 
was administered IV.  Atropine sulfate (0.5 mg) was given by IV 
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and the isoﬂ urane concentration decreased if the heart rate 
fell below 50 bpm. When necessary to ensure equivalent an-
esthesia depth, the volatile agent was increased by 0.2-0.25.
For nausea and vomiting prophylaxis, we gave ondansetron 
(4 mg) by IV and for postoperative pain control, we adminis-
tered 75 mg diclofenac sodium intramuscularly in all patients 
30 minutes before the operation’s end. The bleeding rate was 
determined by the surgeon according to the Fromm–Boezaart 
Quality Scale where: “0”, no bleeding; “1”- there was no 
need to remove blood from the surgical ﬁ eld; “2”- sometimes 
there was the need to remove blood from the surgical ﬁ eld; 
“3” blood was removed from the operation area frequently; 
“4” the ﬁ eld could be visualized only upon blood removal; 
“5”- bleeding did not allow continuation of the operation. In 
addition, surgeon satisfaction was assessed and recorded as: 
“good” = 1; “average” = 2; “bad” = 3.
For calculating gas consumption, we performed a repetitive 
calibration process of the anesthesia device for each patient. 
At the end of the operation, we recorded the total amount of 
isoﬂ urane, N2O, and O2 consumed through calculations made 
by the ADU S/5 anesthesia device. In addition, the amount 
of dexmedetomidine and additional medicine consumed was 
also recorded. Complications such as nausea, vomiting, itching 
and urine retention occurring during the postoperative period 
were also recorded.
The SPSS 13 package program was used to evaluate data 
obtained in this study. Normality analysis of data was per-
formed by the Shapiro-Wilk test. Student’s t-test was used in 
independent groups for the data showing normal distribution 
and the Chi-Square test was used for the variables calculated 
on a categorical basis. P values < 0.05 were considered statis-
tically signiﬁ cant. The patients who participated in the study 
were randomly determined and a neutrality assumption was 
achieved. Before this study, the effect size of 0.85, α = 0.05 
and theoretical power (1-β) = 0.70 values were accepted and 
using the Gpower package program the study was performed 
with 40 subjects where n1 = n2 = 20.
Results
The study groups were matched according to age (year), 
weight, height, operation period, gender, and ASA scores 
(p > 0.05) (Table 1 and 2).
Hemodynamic data showed that in each group heart rates 
decreased after dexmedetomidine loading. After intubation, 
both groups had the same rate of heart rate increase to return 
to or slightly exceed basal values. After intubation, Group A had 
a lower heart rate decrease between 5 and 30 minutes after 
intubation (p < 0.05; Student’s t-test) (Figure 1).
Table 1  Student’s t-test results and comparison of patient characteristics.
Group N 
(n=20)
Group A
 (n=20)
p+
Age (years) 30.5 ± 8.90 34.05 ± 10.27 0.278
Weight (kg) 65.12 ± 13.45 72.40 ± 14.49 0.088
Height (cm) 165.93 ± 5.57 169.27 ± 8.70 0.064
Operation Period (min) 168.12 ± 59.41 156.75 ± 58.49 0.588
Average ± Standard Deviation; + t-test in independent groups.
Table 2  Comparison of patient characteristics and Chi-Square test results.
Group N 
(n=20)
Group A 
(n=20)
p 
(Chi Square)
Gender (F / E) 15/5 9/11 0.074
ASA I / II 8/12 4/16 0.130
* p < 0.05.
Figure 1  Heart rate distribution.
bd: dexmedetomidine before, ad: after dexmedetomidine loading, ai: after intubation, be: before extubation, ae: after extubation.
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There was no signiﬁ cant difference in MAP for each group 
after dexmedetomidine loading. After intubation, MAP was 
higher for minutes 1-15 for Group A (p < 0.05) (Figure 2). 
Group N reached desired hypotension levels ﬁ ve minutes after 
intubation, while Group A reached desired levels 20 minutes 
after intubation. Although we stopped dexmedetomidine in 
the last 30 minutes, MAP remained similar before and after 
intubation (Figure 2).
Beginning just after intubation, Group N’s MAC values 
were slightly higher than Group A’s, with differences at min-
utes one, three, ﬁ ve, 10, and 15 (Figure 3) (p < 0.05). 
Group N FiO2 values were lower than Group A, although 
no group had values that fell by more than 30% during any 
interval.  While Group A FiO2 values were higher between 
ﬁ ve and 60 minutes, by minute 90 Group N had higher values 
(p < 0.05). Between 150 and 240 minutes, values were again 
higher in Group A, albeit with no statistically signiﬁ cant dif-
ference (Figure 4) (p < 0.05).
Fi Iso values were lower in Group N compared to Group 
A, starting at 15 minutes. There were statistical differ-
ences between the values at minute 15 and 30 (Figure 5). 
The groups showed no difference between ETIso and ETCO2 
pressures or P plateau values.  
There was no signiﬁ cant difference between groups with 
respect to dexmedetomidine (mcg), isoﬂ urane (mL) and 
Alfentanil (mcg) values. While the dexmedetomidine and 
isoﬂ urane usage was higher for Group A, the difference was 
not signiﬁ cant (Table 3).
We did not have to increase the gas ﬂ ow, since no de-
crease in oxygen saturation and FiO2 values below 94 or 30%, 
respectively, occurred, and there were no ETCO2 values over 
40 mm Hg. Alfentanil (7 μg.kg-1) was used intravenously for 
three and four patients in Groups N and A, respectively, be-
cause the MAP fell below desired values. At other time points 
there was no signiﬁ cant difference between the groups in 
terms of these data. (p < 0.05). 
At minute 15, during which time surgical incisions oc-
curred, bleeding with a score of one as per the Fromm-
Boezaart Quality Scale was observed for six Group N 
patients and eight Group A patients. There were no dif-
ferences between the groups for other ﬁ ndings or surgeon 
satisfaction.    
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Figure 2  MAP distribution. 
bd: dexmedetomidine before, ad: after dexmedetomidine loading, ai: after intubation, be: before extubation, ae: after 
extubation.
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Figure 3  MAC distribution. 
ai: after intubation, be: before extubation, ae: after extubation.
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Discussion
The major risks in low ﬂ ow anesthesia application include 
hypoxia, use of volatile anesthetics at low or high dosages, 
development of hypercapnia and accumulation of toxic trace 
gases 12. Low ﬂ ow anesthesia methods are recommended 
for minor and average operations and for patients without 
signiﬁ cant complaints at the outset. For this reason, class 
ASA I or II patients were selected. 
When applying low flow methods, devices that can 
monitor and carefully adjust the alarm limit values of air 
line pressure, the gas volume inhaled, FiO2, concentration 
of volatile anesthetic agent and CO2 concentrations should 
be used 12. Here, the ADU S/5 (Datex- Ohmeda®) anesthesia 
device was used, which allows monitoring of these values 
and electronic control of fresh gas ﬂ ow.
In the low ﬂ ow anesthesia method, there is an initial time 
period of 6-8 minutes for high ﬂ ows of fresh gas (4-5 L.min-1), 
which ﬁ lls the system and adjusts the patient’s functional 
residual capacity, actualizes N2O equalization, and allows 
sufﬁ cient anesthesia depth by providing denitrogenization. 
Afterwards, the fresh gas ﬂ ow rate is decreased to 1 L.min-1 
and low ﬂ ow anesthesia is initiated 12. Here, we started 
the low ﬂ ow anesthesia application after 10 minutes of 
denitrogenization. 
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Table 3  Medicine consumption.
Group N (n=20) Group A (n=20) p+
Dexmedetomidine (mcg) 168.12 ± 51.53 174.55 ± 56.66 0.756
Isoﬂ urane (mL) 21.25 ± 13.72 24.16 ± 7.17 0.070
Alfentanil (mcg) 0.18 ± 0.40 0.22 ± 0.42 0.806
Average ± SS; + t-test in independent groups.
ai 5 10 15 30 45 60 90 120 150 180 210 240 be ae1
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Group AGroup N
2,0
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1,0
0,5
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Figure 4  FiO2 distribution. 
ai: after intubation, be: before extubation, ae: after extubation.
Figure 5  Fi Iso distribution. 
ai: after intubation, be: before extubation, ae: after extubation.
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In our study we observed a decrease in hemodynamic 
data before the operation following dexmedetomidine load-
ing, although these values returned to baseline values after 
intubation (even when calculated hemodynamic values were 
high for the group without nitrous oxide, sufﬁ cient anesthesia 
depth and controlled hypotension was achieved). In terms 
of medicine usage, bleeding, and surgeon satisfaction, no 
difference was found between groups.  These ﬁ ndings are 
in agreement with those of other studies 13.
The development of anesthesia devices, increased en-
vironmental sensitivity awareness, anesthetics with new 
features and high costs, coupled with the ﬁ nancial limitations 
of the medical sector worldwide led to the use of low ﬂ ow 
anesthesia methods 14. In low ﬂ ow anesthesia, the air exhaled 
after CO2 absorption, which is used in half-closed systems, 
is re-exhaled to the patient in ratios of at least 50%. This 
situation can be achieved by modern re-inhalation systems 
only if fresh gas ﬂ ow can be decreased 2.0 L.dk-1 15. According 
to the studies, high gas ﬂ ow in the initial phase, which lasts 
10 minutes, is obligatory to ensure that ﬂ ow rates will be 
at least 30% for FiO2, 3.0 L.min
-1 for N2O ﬂ ow and 1.4 L.min
-1 
for oxygen ﬂ ow 16. The isoﬂ urane dose should be adjusted to 
1.5% during this initial phase. If these adjustments are made 
in the ﬁ rst 10 minutes, the general MAC will be 1.3. In our 
study, the MAC value for the group with nitrous oxide was 
similar to this value. This value is AD95 and is accepted as suf-
ﬁ cient anesthesia depth that guarantees that 95% of patients 
won’t react to a skin incision. Aantaa et al. 17 reported that 
dexmedetomidine used in high dosages decreases isoﬂ urane 
MAC to 47 %. These low MAC values can produce hypotension 
at desired levels with lower isoﬂ urane concentrations result-
ing from dexmedetomidine usage in both groups.
By decreasing the ﬂ ow in low ﬂ ow anesthesia, an increase 
could be observed in FiO2 between 30 and 45 minutes with 
a continuous and slow decrease following this baseline in-
crease. When the oxygen alarm limit is reached, oxygen ﬂ ow 
rate must be increased and N2O must be decreased in same 
ratio. In our study no patient experienced a decrease under 
30% for FiO2, probably because 50% oxygen was used in our 
low ﬂ ow application. 
Although Tobias and Berkenbosch 13 state that after 
stopping dexmedetomidine infusion patients’ hemodynamic 
parameters returned to basal values within 7 minutes, in 
our study this period continued after extubation. If low ﬂ ow 
anesthesia were maintained, this prolongation would be 
expected since the decrease in anesthetic concentrations is 
slow and late. Also, the reported isoﬂ urane concentration 
was lower than those used here.
Isoﬂ urane is believed to be the most suitable volatile 
anesthetic for creating hypotension in healthy patients 18. 
In studies on both humans and animals, isoﬂ urane was 
shown to decrease blood pressure by decreasing vascular 
resistance 19,20. Macnab et al. 21 stated that MAP could be 
decreased efﬁ ciently and the stress response weakened 
when isoﬂ urane was  used in cerebral aneurysm surgery. 
The limit value of blood ﬂ ow that creates ischemia for 
patients undergoing carotid endarterectomy is lower for 
isoﬂ urane compared to enﬂ urane and halothane. Newman 
et al. 22 stated that for cerebral aneurysm clips applied to 
patients, isoﬂ urane has beneﬁ cial effects on the cerebral 
oxygen presentation–requirement ratio. Haraldsted et al.23 
also stated that the maximum limit of MAC value at which 
these beneﬁ cial effects were seen is 2.5. 
Madsen et al. 6 reported that rebound hypertension occurs 
after stopping isoﬂ urane for cerebral aneurysm clips applied 
to patients and isoﬂ urane alone could not prevent sympathet-
ic stimulation with rebound hypertension prevented by the 
α2-agonist clonidine. Also, because isoﬂ urane does not com-
pletely block baroreceptor reﬂ exes, it can obstruct rebound 
sympathetic stimulation to reach desired hypotension levels 
and resistance can develop against the hypertensive effects 
of isoﬂ urane 6. The combination of isoﬂ urane with agents to 
maintain cardiac output will be more suitable than using it 
alone in higher dosages 24. Toivenen and Kaukinen evaluated 
the ability of clonidine to decrease the use of hypertensive 
agents in middle ear surgery and found that clonidine pre-
medication at 4-5 μg.kg-1 decreased the usage of labetalol 
or isoﬂ urane in hypotension while also preventing increases 
in plasma catecholamine levels and causing the subsequent 
development of rebound hypertension 7. Woodcock et al. 8 
administered clonidine premedication (0.6 mg oral) with 
isoﬂ urane (2%) to middle ear and nasal surgery patients 2 
hours before surgery and then tried to achieve hypertensive 
anesthesia by administering 3% isoﬂ urane. The premedica-
tion decreased the amount of hypotensive needed and the 
isoﬂ urane amount required to obtain hypotension was also 
decreased. 
The combination of isoflurane with medicines that 
block α-adrenergic or β-adrenergic receptors decreases 
the negative effects compared to single use of isoﬂ urane 
as a hypertensive 25,26. Thus, isoﬂ urane should be used as 
adjuvant medicine in low concentrations while using con-
trolled hypertension. This method has advantages such as 
decreasing cerebral metabolism and protecting pulmonary 
gas exchange 27.
Dexmedetomidine is a speciﬁ c α2-adrenoceptor agonist. 
In addition to being generally used in mechanical ventilation 
of adults, it is frequently used after cardiac surgery as a 
sedative. The anxiolytic and anesthetic characteristics and 
its ability to enhance the effects of opioids make dexme-
detomidine a part of a balanced anesthetic management. 
Dexmedetomidine also could be beneﬁ cial for hypotension 
because it decreases average artery pressure and heart rate 13. 
Premedication with dexmedetomidine at 1.2-2.5 μg.kg-1 dos-
ages inhibits the cardiovascular response at laryngoscopy 
and tracheal intubation 28. Intravenous dexmedetomidine 
(0.6 μg.kg-1) given 10 minutes before anesthesia induction 
decreases the stress response 29.  Compatible with results 
obtained with normotensive patients, the stress response to 
laryngoscopy and endotracheal intubation was also suppressed 
when dexmedetomidine was administered 10 minutes before 
anesthesia. 
In middle ear surgery, disruption of intra-operative vision 
due to bleeding is a serious problem. Ülger et al. 10 reported 
that dexmedetomidine enables better surgical vision and 
exposure compared to nitroglycerine not only by decreasing 
blood pressure, but also by enhancing capillary blood ﬂ ow and 
venous pressure. In our evaluations, Group N (with nitrous 
oxide) had bleeding in six patients as compared to eight 
patients in Group A. Membrane placement in tympanoplasty 
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operations generally occurs between minute 60 and 100 
and takes approximately 20 to 30 minutes. During this time 
period, both groups had bleeding scores of zero and desired 
average artery pressures. Together, these results indicate 
that the hypotension level achieved is sufﬁ cient and that 
dexmedetomidine is effective for controlled hypotension.
During tympanoplasty, the middle ear is open to the 
atmosphere and there is no pressure increase. When the 
tympanic membrane is placed, the middle ear again becomes 
a closed space. If nitrous oxide diffuses to this space, pres-
sure in the middle ear will be increased and the membrane 
could detach from its placement site. If the nitrous oxide ﬂ ow 
is stopped after membrane placement, a negative pressure 
could develop and the membrane may collapse from within. 
For both reasons, nitrous oxide should either be avoided dur-
ing tympanoplasty or stopped before graft placement 10.
Low ﬂ ow anesthesia methods minimize problems such 
as release of nitrous oxide to the atmosphere and operating 
room contamination 30-32, while maintaining the amount of gas 
received by patients and keeping harmful results unchanged. 
To prevent these problems, the use of nitrous oxide should 
be avoided in all inhalation anesthesia administrations, in-
cluding low ﬂ ow anesthesia methods. Analgesia loss arising 
from stopping nitrous oxide ﬂ ow could be compensated by 
opioid usage and hypnotic effect loss could be compensated 
by increasing volatile agent concentration 12,13.
In conclusion, in low ﬂ ow anesthesia for middle ear sur-
gery the desired mean arterial pressure could be achieved 
in both groups by using isoﬂ urane and dexmedetomidine 
although the desired mean arterial pressure was reached 
later for the group without nitrous oxide. However, during 
surgical membrane placement that occurs in the last phases 
of the operation, the surgeon would not be affected by this 
delay, making dexmedetomidine a suitable agent to provide 
controlled hypotension without nitrous oxide in middle ear 
surgery. 
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